相关实验视频

Updated: May 26, 2025

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

鲁特卡平通过激活STING途径和提升CD8+T细胞来抑制非小细胞肺癌的进展

Ze-Bo Jiang^1,2, Qing-Hua He³, Li-Ping Kang^1,2

¹Zhuhai Hospital of Integrated Traditional Chinese and Western Medicine, Zhuhai, Guangdong, China.

Chemical biology & drug design

|February 24, 2025

概括

鲁特卡 (Rutecarpine,简称RUT) 是一种非小细胞肺癌 (NSCLC) 的抗癌药物. 它通过激活STING通路和促进CD8+T细胞,诱导细胞灭亡并抑制瘤生长.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
免疫学免疫学免疫学

背景情况:

非小细胞肺癌 (NSCLC) 是全球癌症死亡的主要原因.
鲁特卡 (RUT) 是一种天然类化合物,具有抗癌潜力,但其在NSCLC中的机制尚未完全理解.

研究的目的:

为了阐明Rutecarpine (RUT) 在非小细胞肺癌 (NSCLC) 中的抗瘤机制.
评估RUT作为NSCLC的抗癌药物的治疗潜力.

主要方法:

研究RUT对NSCLC细胞活力,细胞亡和反应性氧物种 (ROS) 生产的影响.
分析了RUT对CXCL10,CCL5,STING通路激活和NSCLC细胞中PD-L1水平的影响.
在小鼠NSCLC模型中评估RUT在抑制瘤生长和调节免疫反应方面的有效性.

主要成果:

RUT显著降低了NSCLC细胞活力,并通过ROS刺激和线粒体功能障碍诱导了亡.
RUT治疗增加了CXCL10和CCL5的产生,激活了STING通路,并降低了NSCLC细胞中的PD-L1水平.
在体内,RUT抑制了瘤生长,并在小鼠NSCLC模型中增强了CD8+T细胞的透.

结论:

鲁特卡通过ROS调节,免疫通路激活和PD-L1降低调节显示出显著的抗NSCLC活性.
作为非小细胞肺癌的抗癌剂,RUT显示出有前途的治疗潜力.

关键词:

CD8+ T T8+ CD8+ T T8+ CD8+ T T T8+ CD8+ CD8+ CD8+ T T T8+ CD8+ CD8+ CD8+ CD8+ CD8+ T T 在CXCL10中,CXCL10是CXCL10中的一个.刺痛是一种刺痛.肺癌是一种肺癌.路德卡尔类类类药物

更多相关视频

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Published on: February 24, 2023

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...